董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Wyzga | 男 | Director | 66 | 未披露 | 未持股 | 2021-08-02 |
| Rene Russo | 女 | Co-Founder, Director and Chair of the Board | 46 | 8.43万美元 | 未持股 | 2021-08-02 |
| Tillman U. Gerngross | 男 | Co-Founder, Chief Executive Officer and Director | 57 | 0.59万美元 | 未持股 | 2021-08-02 |
| Terrance McGuire | 男 | Director | 65 | 未披露 | 未持股 | 2021-08-02 |
| Ajay Royan | 男 | Director | 41 | 未披露 | 未持股 | 2021-08-02 |
| Howard Mayer | 男 | Director | 58 | 1.41万美元 | 未持股 | 2021-08-02 |
| Anand Shah | -- | Director | 41 | 未披露 | 未持股 | 2021-08-02 |
| Tom Heyman | 男 | Director | 65 | 未披露 | 未持股 | 2021-08-02 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jane Pritchett Henderson | 女 | Chief Financial Officer | 56 | 未披露 | 未持股 | 2021-08-02 |
| Rene Russo | 女 | Co-Founder, Director and Chair of the Board | 46 | 8.43万美元 | 未持股 | 2021-08-02 |
| Tillman U. Gerngross | 男 | Co-Founder, Chief Executive Officer and Director | 57 | 0.59万美元 | 未持股 | 2021-08-02 |
| Lynn Connolly | -- | Chief Medical Officer | 54 | 84.58万美元 | 未持股 | 2021-08-02 |
| Rebecca Dabora | -- | Chief Technology & Manufacturing Officer | 62 | 58.31万美元 | 未持股 | 2021-08-02 |
| David Hering | 男 | Chief Operating Officer | 47 | 未披露 | 未持股 | 2021-08-02 |
| Elham. Hershberger | -- | Chief Development Officer | 53 | 未披露 | 未持股 | 2021-08-02 |
董事简历
中英对照 | 中文 | 英文- Michael Wyzga
-
Michael Wyzga，他是现任生物技术顾问，并拥有生物技术行业的丰富经验。他曾担任Radius Health公司（生物制药公司）的总裁兼首席执行官、董事会成员（从2011年11月到2013年11月）。此前，他于1999年3月加入Genzyme公司，在那里他曾担任财务执行副总裁（从2003年5月到2011年11月），以及首席财务官（从1999年7月到2011年6月）。他此前曾任职于Idenix Pharmaceuticals公司、Prosensa Holding公司的董事会。他目前任职于Oncomed Pharmaceuticals公司、Akebia Therapeutics公司、Exact Sciences公司的董事会。他持有Providence College的工商管理硕士学位，以及Suffolk University的学士学位。
Michael Wyzga has served as a member of our board of directors since July 2021. Mr. Wyzga currently serves as the President of MSW Consulting, Inc. since November 2013. Mr. Wyzga also currently serves as a member and chair of the board of directors for GenSight Biologics S.A. since July 2015 and for X4 Pharmaceuticals, Inc. since July 2018. Mr. Wyzga also currently serves as a member of the board and chair of the audit committee for LogicBio Therapeutics since December 2018 and for Exact Science, Inc. since February 2015. Mr. Wyzga serves as a member and deputy chair of the board of Mereo Pharmaceuticals since April 2019 and prior to that, Mr. Wyzga served as a member of the board of directors of OncoMed from October 2013 to April 2019. Mr. Wyzga received an M.B.A. from Providence College and a B.S. from Suffolk University. - Michael Wyzga，他是现任生物技术顾问，并拥有生物技术行业的丰富经验。他曾担任Radius Health公司（生物制药公司）的总裁兼首席执行官、董事会成员（从2011年11月到2013年11月）。此前，他于1999年3月加入Genzyme公司，在那里他曾担任财务执行副总裁（从2003年5月到2011年11月），以及首席财务官（从1999年7月到2011年6月）。他此前曾任职于Idenix Pharmaceuticals公司、Prosensa Holding公司的董事会。他目前任职于Oncomed Pharmaceuticals公司、Akebia Therapeutics公司、Exact Sciences公司的董事会。他持有Providence College的工商管理硕士学位，以及Suffolk University的学士学位。
- Michael Wyzga has served as a member of our board of directors since July 2021. Mr. Wyzga currently serves as the President of MSW Consulting, Inc. since November 2013. Mr. Wyzga also currently serves as a member and chair of the board of directors for GenSight Biologics S.A. since July 2015 and for X4 Pharmaceuticals, Inc. since July 2018. Mr. Wyzga also currently serves as a member of the board and chair of the audit committee for LogicBio Therapeutics since December 2018 and for Exact Science, Inc. since February 2015. Mr. Wyzga serves as a member and deputy chair of the board of Mereo Pharmaceuticals since April 2019 and prior to that, Mr. Wyzga served as a member of the board of directors of OncoMed from October 2013 to April 2019. Mr. Wyzga received an M.B.A. from Providence College and a B.S. from Suffolk University.
- Rene Russo
-
Rene Russo自2016年4月起担任我们的董事会成员，并于2016年4月至2018年11月担任Arsanis的总裁兼首席执行官。Russo博士还于2015年7月至2016年4月担任Arsanis的首席发展官。自2019年5月起，Russo博士担任Akrevia Therapeutics，LLC（一家私人控股的生物制药公司，专注于开发免疫肿瘤疗法）的首席执行官。在此之前，Russo博士从2003年到2015年5月被默克收购，在CubistPharmaceuticals，Inc.担任了11年多的各种职务，该公司是一家公共制药开发公司，专注于传染病疗法的开发和商业化，最近被默克收购为其全球医疗事务Vice President。从1999年到2004年，她在百时美施贵宝公司（Bristol-Myers Squibb）担任越来越重要的职务，在那里她开始了她的行业职业生涯，担任工业制药传染病博士后。在加入生物技术行业之前，Russo博士在Robert Wood Johnson University Hospital和Princeton Hospital担任临床职位。Russo医生拿到了她的药以及Rutgers University的B.S.。
Rene Russo has served as our chief executive officer and as a member of our board of directors since May 2019 and as our president since May 2021. She has served as founder and chairman of the board of directors of Adagio Therapeutics, Inc., a biotechnology company, since June 2020. Dr. Russo served as entrepreneur-in-residence at New Enterprise Associates, a venture capital firm, from November 2018 to November 2019. Prior to that, she served as president and chief executive officer of Arsanis, Inc., or Arsanis, a biopharmaceutical company, from April 2016 to November 2018 and as its chief development officer from July 2015 until April 2016. Prior to joining Arsanis, Dr. Russo served in various roles of increasing responsibility over an 11-year period at Cubist Pharmaceuticals, Inc., a pharmaceutical development company, focused on the development and commercialization of infectious disease therapeutics, from 2003 until its acquisition by Merck Research Laboratories, or Merck, a healthcare company, in May 2015 most recently as its vice president, global medical affairs. Dr. Russo served as a member of the board of directors of Arsanis, Inc. since April 2016 and continues to serve as a member of X4 Pharmaceuticals, Inc., a biopharmaceutical company, following its merger with Arsanis in March 2019. Prior to joining the biotechnology industry, Dr. Russo held clinical positions at Robert Wood Johnson University Hospital and Princeton Hospital. Dr. Russo received her Pharm.D. and B.S. from Rutgers University. - Rene Russo自2016年4月起担任我们的董事会成员，并于2016年4月至2018年11月担任Arsanis的总裁兼首席执行官。Russo博士还于2015年7月至2016年4月担任Arsanis的首席发展官。自2019年5月起，Russo博士担任Akrevia Therapeutics，LLC（一家私人控股的生物制药公司，专注于开发免疫肿瘤疗法）的首席执行官。在此之前，Russo博士从2003年到2015年5月被默克收购，在CubistPharmaceuticals，Inc.担任了11年多的各种职务，该公司是一家公共制药开发公司，专注于传染病疗法的开发和商业化，最近被默克收购为其全球医疗事务Vice President。从1999年到2004年，她在百时美施贵宝公司（Bristol-Myers Squibb）担任越来越重要的职务，在那里她开始了她的行业职业生涯，担任工业制药传染病博士后。在加入生物技术行业之前，Russo博士在Robert Wood Johnson University Hospital和Princeton Hospital担任临床职位。Russo医生拿到了她的药以及Rutgers University的B.S.。
- Rene Russo has served as our chief executive officer and as a member of our board of directors since May 2019 and as our president since May 2021. She has served as founder and chairman of the board of directors of Adagio Therapeutics, Inc., a biotechnology company, since June 2020. Dr. Russo served as entrepreneur-in-residence at New Enterprise Associates, a venture capital firm, from November 2018 to November 2019. Prior to that, she served as president and chief executive officer of Arsanis, Inc., or Arsanis, a biopharmaceutical company, from April 2016 to November 2018 and as its chief development officer from July 2015 until April 2016. Prior to joining Arsanis, Dr. Russo served in various roles of increasing responsibility over an 11-year period at Cubist Pharmaceuticals, Inc., a pharmaceutical development company, focused on the development and commercialization of infectious disease therapeutics, from 2003 until its acquisition by Merck Research Laboratories, or Merck, a healthcare company, in May 2015 most recently as its vice president, global medical affairs. Dr. Russo served as a member of the board of directors of Arsanis, Inc. since April 2016 and continues to serve as a member of X4 Pharmaceuticals, Inc., a biopharmaceutical company, following its merger with Arsanis in March 2019. Prior to joining the biotechnology industry, Dr. Russo held clinical positions at Robert Wood Johnson University Hospital and Princeton Hospital. Dr. Russo received her Pharm.D. and B.S. from Rutgers University.
- Tillman U. Gerngross
-
TillmanU.Gerngross于2010年共同创立了Arsanis，并于2010年8月至2013年8月和2015年12月至2016年4月担任我们的总裁。自2010年8月起担任董事会主席。在加入我们之前，Gerngross博士共同创立了Adimab，LLC，并自2007年以来担任其首席执行官兼董事会主席。Gerngross博士联合创立了多家其他生物技术公司，包括Alector，LLC和Avitide，Inc.，在那里他分别自2014年和2013年以来担任其董事会主席。Gerngross博士目前是SV Health Investors，LLC的风险合伙人，他于2006年加入该公司。Gerngross博士联合创立了Glycofi，Inc.，并从2000年到2006年担任其首席科学官，直到它被Merck收购。Gerngross博士目前任教于生物和化学系，以及达特茅斯学院（Dartmouth College）的工程学院，他自1998年以来一直在那里任教。Gerngross博士就读于奥地利维也纳技术大学（Technical University of Vienna，Austria），在那里他获得化学工程学士学位/硕士学位，后来获得分子生物学博士学位。
Tillman U. Gerngross is our co-founder and has served as a member of our board of directors and as our Chief Executive Officer since June 2020. Dr. Gerngross is a founder, director and executive officer of numerous biotechnology companies. He is a co-founder of Adimab, LLC and has served as its Chief Executive Officer and as a director since 2007. He is also a co-founder and Chairman of Avitide, Inc. since August 2012 a co-founder and Chairman of Alector, Inc. since September 2017 a co-founder, President and Chairman of Amagma, Inc. since August 2019 and a co-founder, President and Chairman of Ankyra Therapeutics, Inc. since November 2019. Dr. Gerngross is currently a Venture Partner at SV Life Sciences Advisors, LLC, which he joined in 2006. Dr. Gerngross co-founded GlycoFi, Inc. and served as its Chief Scientific Officer from 2000 to 2006 until it was acquired by Merck & Company, Inc. Dr. Gerngross currently teaches at the Thayer School of Engineering, at Dartmouth College, where he has taught since 1998. Dr. Gerngross received a B.S. and M.S. in Chemical Engineering and a Ph.D. in Molecular Biology from Technical University of Vienna. - TillmanU.Gerngross于2010年共同创立了Arsanis，并于2010年8月至2013年8月和2015年12月至2016年4月担任我们的总裁。自2010年8月起担任董事会主席。在加入我们之前，Gerngross博士共同创立了Adimab，LLC，并自2007年以来担任其首席执行官兼董事会主席。Gerngross博士联合创立了多家其他生物技术公司，包括Alector，LLC和Avitide，Inc.，在那里他分别自2014年和2013年以来担任其董事会主席。Gerngross博士目前是SV Health Investors，LLC的风险合伙人，他于2006年加入该公司。Gerngross博士联合创立了Glycofi，Inc.，并从2000年到2006年担任其首席科学官，直到它被Merck收购。Gerngross博士目前任教于生物和化学系，以及达特茅斯学院（Dartmouth College）的工程学院，他自1998年以来一直在那里任教。Gerngross博士就读于奥地利维也纳技术大学（Technical University of Vienna，Austria），在那里他获得化学工程学士学位/硕士学位，后来获得分子生物学博士学位。
- Tillman U. Gerngross is our co-founder and has served as a member of our board of directors and as our Chief Executive Officer since June 2020. Dr. Gerngross is a founder, director and executive officer of numerous biotechnology companies. He is a co-founder of Adimab, LLC and has served as its Chief Executive Officer and as a director since 2007. He is also a co-founder and Chairman of Avitide, Inc. since August 2012 a co-founder and Chairman of Alector, Inc. since September 2017 a co-founder, President and Chairman of Amagma, Inc. since August 2019 and a co-founder, President and Chairman of Ankyra Therapeutics, Inc. since November 2019. Dr. Gerngross is currently a Venture Partner at SV Life Sciences Advisors, LLC, which he joined in 2006. Dr. Gerngross co-founded GlycoFi, Inc. and served as its Chief Scientific Officer from 2000 to 2006 until it was acquired by Merck & Company, Inc. Dr. Gerngross currently teaches at the Thayer School of Engineering, at Dartmouth College, where he has taught since 1998. Dr. Gerngross received a B.S. and M.S. in Chemical Engineering and a Ph.D. in Molecular Biology from Technical University of Vienna.
- Terrance McGuire
-
Terrance McGuire自2017年12月以来一直担任我们的董事会成员。McGuire先生担任Polaris Partners的普通合伙人，这是一家他于1996年联合创立的风险投资公司。他目前任职于Alector，Inc.和Cyclerion公司的董事会，此前曾任职于Acceleron Pharma公司、Arsanis公司、IronwoodPharmaceuticals，Inc.公司和Pulmatrix，Inc.公司的董事会。McGuire先生还担任麻省理工学院（Massachusetts Institute of Technology）David H.Koch综合癌症研究所的董事会成员，哈佛商学院Arthur Rock创业中心和梦百合倡议咨询委员会以及达特茅斯学院Thayer工程学院顾问委员会。McGuire先生拥有霍巴特学院（Hobart College）的物理学和经济学学士学位，达特茅斯学院（Thayer School at Dartmouth College）的工程学硕士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
Terrance McGuire has served as a member of our board of directors since October 2020. Mr. McGuire is a Founding Partner of Polaris Partners, a venture capital firm investing in technology and healthcare companies, since 1996. In addition, Mr. McGuire serves as chairman of the board of directors of Ironwood Pharmaceuticals, Inc. and has served as a director since 1998. Mr. McGuire also currently serves on the boards of directors of Acceleron Pharma, Inc. since 2005 Pulmatrix, Inc. since May 2016 and Adimab, LLC since August 2007. Mr. McGuire received a B.S. in physics and economics from Hobart College, an M.B.A. from Harvard Business School and an M.S. in Engineering from the Thayer School at Dartmouth College. - Terrance McGuire自2017年12月以来一直担任我们的董事会成员。McGuire先生担任Polaris Partners的普通合伙人，这是一家他于1996年联合创立的风险投资公司。他目前任职于Alector，Inc.和Cyclerion公司的董事会，此前曾任职于Acceleron Pharma公司、Arsanis公司、IronwoodPharmaceuticals，Inc.公司和Pulmatrix，Inc.公司的董事会。McGuire先生还担任麻省理工学院（Massachusetts Institute of Technology）David H.Koch综合癌症研究所的董事会成员，哈佛商学院Arthur Rock创业中心和梦百合倡议咨询委员会以及达特茅斯学院Thayer工程学院顾问委员会。McGuire先生拥有霍巴特学院（Hobart College）的物理学和经济学学士学位，达特茅斯学院（Thayer School at Dartmouth College）的工程学硕士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
- Terrance McGuire has served as a member of our board of directors since October 2020. Mr. McGuire is a Founding Partner of Polaris Partners, a venture capital firm investing in technology and healthcare companies, since 1996. In addition, Mr. McGuire serves as chairman of the board of directors of Ironwood Pharmaceuticals, Inc. and has served as a director since 1998. Mr. McGuire also currently serves on the boards of directors of Acceleron Pharma, Inc. since 2005 Pulmatrix, Inc. since May 2016 and Adimab, LLC since August 2007. Mr. McGuire received a B.S. in physics and economics from Hobart College, an M.B.A. from Harvard Business School and an M.S. in Engineering from the Thayer School at Dartmouth College.
- Ajay Royan
-
Ajay Royan自2020年10月起担任我们的董事会成员。自2012年6月以来，Royan先生一直担任Mithril Capital Management LLC（一家投资于科技公司的风险投资公司）的管理普通合伙人兼创始人，以及Mithril Capital Management LLC或其附属公司投资的几家私人公司的董事会成员。此外，Royan先生自2014年9月起担任Adimab，LLC的董事，自2016年6月起担任Blacksky Holdings，Inc.的董事。Royan先生在Oak Ridge国家实验室的科学顾问委员会，Fulbright Canada的董事会，以及国家科学、工程和医学研究院的院长。Royan先生获得了耶鲁大学的学士学位。
Ajay Royan has served as a member of our board of directors since October 2020. Mr. Royan has served as Managing General Partner and Founder of Mithril Capital Management LLC, a venture capital firm investing in technology companies, since June 2012 and on the board of directors of several private companies in which Mithril Capital Management LLC or its affiliates have invested. In addition, Mr. Royan has served as a director of Adimab, LLC since September 2014 and has served as a director of Blacksky Holdings, Inc. since June 2016. Mr. Royan serves on the Science Advisory Board of the Oak Ridge National Laboratory, the board of directors of Fulbright Canada, and the Presidents’ Circle of the National Academies of Science, Engineering, and Medicine. Mr. Royan received a B.A. from Yale University. - Ajay Royan自2020年10月起担任我们的董事会成员。自2012年6月以来，Royan先生一直担任Mithril Capital Management LLC（一家投资于科技公司的风险投资公司）的管理普通合伙人兼创始人，以及Mithril Capital Management LLC或其附属公司投资的几家私人公司的董事会成员。此外，Royan先生自2014年9月起担任Adimab，LLC的董事，自2016年6月起担任Blacksky Holdings，Inc.的董事。Royan先生在Oak Ridge国家实验室的科学顾问委员会，Fulbright Canada的董事会，以及国家科学、工程和医学研究院的院长。Royan先生获得了耶鲁大学的学士学位。
- Ajay Royan has served as a member of our board of directors since October 2020. Mr. Royan has served as Managing General Partner and Founder of Mithril Capital Management LLC, a venture capital firm investing in technology companies, since June 2012 and on the board of directors of several private companies in which Mithril Capital Management LLC or its affiliates have invested. In addition, Mr. Royan has served as a director of Adimab, LLC since September 2014 and has served as a director of Blacksky Holdings, Inc. since June 2016. Mr. Royan serves on the Science Advisory Board of the Oak Ridge National Laboratory, the board of directors of Fulbright Canada, and the Presidents’ Circle of the National Academies of Science, Engineering, and Medicine. Mr. Royan received a B.A. from Yale University.
- Howard Mayer
-
Howard Mayer自2020年8月起担任我们的董事会成员。此外，Mayer博士自2019年8月起在Entasis Therapeutics HoldingsInc.董事会任职。Mayer博士自2019年12月起担任Ipsen Biopharmaceuticals，Inc.的执行副总裁、研究与开发主管。在加入Ipsen之前，Mayer博士从2018年4月到2019年11月担任Shire Pharmaceuticals，Inc.（Shire）的高级副总裁、首席医疗官和神经科学部门研发全球主管，直到2019年被武田制药公司收购。在此之前，Mayer博士从2017年8月到2018年1月担任Shire的高级副总裁兼全球研究与开发主管，从2013年8月到2017年8月担任Shire的高级副总裁兼全球临床开发主管。梅耶尔博士获得了宾夕法尼亚大学的学士学位和阿尔伯特·爱因斯坦医学院的硕士学位。
Howard Mayer has served as a member of our board of directors since August 2020. In addition, Dr. Mayer has served on the board of directors of Entasis Therapeutics Holdings Inc. since August 2019. Dr. Mayer has served as the Executive Vice President, Head of Research and Development for Ipsen Biopharmaceuticals, Inc. since December 2019. Prior to joining Ipsen, Dr. Mayer served as the Senior Vice President, Chief Medical Officer and Global Head of Research & Development, Neuroscience Division at Shire Pharmaceuticals, Inc., or Shire, from April 2018 to November 2019 until it was acquired by Takeda Pharmaceutical Company in 2019. Prior to that position, Dr. Mayer served as a Senior Vice President and Head of Global Research and Development at Shire from August 2017 to January 2018 and as a Senior Vice President and Head of Global Clinical Development at Shire from August 2013 to August 2017. Dr. Mayer received a B.A. from the University of Pennsylvania and an M.D. from Albert Einstein College of Medicine. - Howard Mayer自2020年8月起担任我们的董事会成员。此外，Mayer博士自2019年8月起在Entasis Therapeutics HoldingsInc.董事会任职。Mayer博士自2019年12月起担任Ipsen Biopharmaceuticals，Inc.的执行副总裁、研究与开发主管。在加入Ipsen之前，Mayer博士从2018年4月到2019年11月担任Shire Pharmaceuticals，Inc.（Shire）的高级副总裁、首席医疗官和神经科学部门研发全球主管，直到2019年被武田制药公司收购。在此之前，Mayer博士从2017年8月到2018年1月担任Shire的高级副总裁兼全球研究与开发主管，从2013年8月到2017年8月担任Shire的高级副总裁兼全球临床开发主管。梅耶尔博士获得了宾夕法尼亚大学的学士学位和阿尔伯特·爱因斯坦医学院的硕士学位。
- Howard Mayer has served as a member of our board of directors since August 2020. In addition, Dr. Mayer has served on the board of directors of Entasis Therapeutics Holdings Inc. since August 2019. Dr. Mayer has served as the Executive Vice President, Head of Research and Development for Ipsen Biopharmaceuticals, Inc. since December 2019. Prior to joining Ipsen, Dr. Mayer served as the Senior Vice President, Chief Medical Officer and Global Head of Research & Development, Neuroscience Division at Shire Pharmaceuticals, Inc., or Shire, from April 2018 to November 2019 until it was acquired by Takeda Pharmaceutical Company in 2019. Prior to that position, Dr. Mayer served as a Senior Vice President and Head of Global Research and Development at Shire from August 2017 to January 2018 and as a Senior Vice President and Head of Global Clinical Development at Shire from August 2013 to August 2017. Dr. Mayer received a B.A. from the University of Pennsylvania and an M.D. from Albert Einstein College of Medicine.
- Anand Shah
-
Anand Shah自2021年6月起担任我们的董事会成员。2020年1月至2021年1月，Shah博士担任美国食品和药物管理局医疗和科学事务副专员。Shah博士自2021年1月起担任摩根士丹利的高级顾问。Shah博士此前曾于2017年10月至2019年1月担任医疗保险和医疗补助创新中心的首席医疗官，并于2019年1月至2020年1月担任医疗保险和医疗补助服务中心的高级医疗顾问。2017年3月至2020年1月，Shah博士在宾夕法尼亚大学伦纳德·戴维健康经济研究所担任兼职高级研究员。沙阿博士获得了宾夕法尼亚大学的医学博士学位，哈佛大学公共卫生学院的医疗管理和政策硕士学位，杜克大学的经济学学士学位。
Anand Shah has served as a member of our board of directors since June 2021. Dr. Shah served as the Deputy Commissioner for Medical and Scientific Affairs at the U.S. Food and Drug Administration from January 2020 to January 2021. Dr. Shah has served as a senior advisor to Morgan Stanley since January 2021. Dr. Shah previously served as Chief Medical Officer of the Center for Medicare and Medicaid Innovation from October 2017 to January 2019 and Senior Medical Advisor from January 2019 to January 2020 both at the Centers for Medicare and Medicaid Services. Dr. Shah served as an Adjunct Senior Fellow at the Leonard David Institute of Health Economics at the University of Pennsylvania from March 2017 to January 2020. Dr. Shah received an M.D. from University of Pennsylvania, an M.P.H. in Health Care Management and Policy from the Harvard School of Public Health and a B.S. in Economics from Duke University. - Anand Shah自2021年6月起担任我们的董事会成员。2020年1月至2021年1月，Shah博士担任美国食品和药物管理局医疗和科学事务副专员。Shah博士自2021年1月起担任摩根士丹利的高级顾问。Shah博士此前曾于2017年10月至2019年1月担任医疗保险和医疗补助创新中心的首席医疗官，并于2019年1月至2020年1月担任医疗保险和医疗补助服务中心的高级医疗顾问。2017年3月至2020年1月，Shah博士在宾夕法尼亚大学伦纳德·戴维健康经济研究所担任兼职高级研究员。沙阿博士获得了宾夕法尼亚大学的医学博士学位，哈佛大学公共卫生学院的医疗管理和政策硕士学位，杜克大学的经济学学士学位。
- Anand Shah has served as a member of our board of directors since June 2021. Dr. Shah served as the Deputy Commissioner for Medical and Scientific Affairs at the U.S. Food and Drug Administration from January 2020 to January 2021. Dr. Shah has served as a senior advisor to Morgan Stanley since January 2021. Dr. Shah previously served as Chief Medical Officer of the Center for Medicare and Medicaid Innovation from October 2017 to January 2019 and Senior Medical Advisor from January 2019 to January 2020 both at the Centers for Medicare and Medicaid Services. Dr. Shah served as an Adjunct Senior Fellow at the Leonard David Institute of Health Economics at the University of Pennsylvania from March 2017 to January 2020. Dr. Shah received an M.D. from University of Pennsylvania, an M.P.H. in Health Care Management and Policy from the Harvard School of Public Health and a B.S. in Economics from Duke University.
- Tom Heyman
-
Tom Heyman自2021年6月起担任我们的董事会成员。Heyman先生此前曾于2015年4月至2019年9月担任强生公司’；S Corporate Venture Capital Group的总裁，并于1992年3月至2015年3月担任强生公司’；S Pharmaceutical Group的全球业务开发主管。此外，Heyman先生曾于2008年11月至2016年11月担任Janssen Pharmaceuticals的首席执行官。Heyman先生自2020年12月起担任OptiNose，Inc.的董事，自2020年6月起担任AkeroTherapeutics，Inc.的董事。Heyman先生从Katholieke University Leuven获得了法学硕士学位。
Tom Heyman has served as a member of our board of directors since June 2021. Mr. Heyman previously served as the President of Johnson & Johnson’s Corporate Venture Capital Group from April 2015 to September 2019 and as the Global Head of Business Development for Johnson & Johnson’s Pharmaceutical Group from March 1992 to March 2015. In addition, Mr. Heyman previously served as Chief Executive Officer of Janssen Pharmaceuticals from November 2008 to November 2016. Mr. Heyman has served as a director of OptiNose, Inc. since December 2020 and a director of Akero Therapeutics, Inc. since June 2020. Mr. Heyman received his Master of Laws from Katholieke Universiteit Leuven. - Tom Heyman自2021年6月起担任我们的董事会成员。Heyman先生此前曾于2015年4月至2019年9月担任强生公司’；S Corporate Venture Capital Group的总裁，并于1992年3月至2015年3月担任强生公司’；S Pharmaceutical Group的全球业务开发主管。此外，Heyman先生曾于2008年11月至2016年11月担任Janssen Pharmaceuticals的首席执行官。Heyman先生自2020年12月起担任OptiNose，Inc.的董事，自2020年6月起担任AkeroTherapeutics，Inc.的董事。Heyman先生从Katholieke University Leuven获得了法学硕士学位。
- Tom Heyman has served as a member of our board of directors since June 2021. Mr. Heyman previously served as the President of Johnson & Johnson’s Corporate Venture Capital Group from April 2015 to September 2019 and as the Global Head of Business Development for Johnson & Johnson’s Pharmaceutical Group from March 1992 to March 2015. In addition, Mr. Heyman previously served as Chief Executive Officer of Janssen Pharmaceuticals from November 2008 to November 2016. Mr. Heyman has served as a director of OptiNose, Inc. since December 2020 and a director of Akero Therapeutics, Inc. since June 2020. Mr. Heyman received his Master of Laws from Katholieke Universiteit Leuven.
高管简历
中英对照 | 中文 | 英文- Jane Pritchett Henderson
Jane Pritchett Henderson，亨德森女士自2017年1月起担任我们的首席财务官兼高级副总裁，企业发展。在加入我们之前，亨德森女士曾担任Kolltan制药公司的高级副总裁，首席财务官兼商务官，于2013年2月加入这家私人控股的生物制药公司，并于2016年11月领导将Kolltan出售给Celldex Pharmaceuticals，Inc.。此前，2010年6月至2012年6月，Henderson女士担任ISTAPharmaceuticals，Inc.（一家公开上市的制药公司）的业务发展Vice President，当时ISTA Pharmaceuticals被Bausch+Lomb收购。在加入ista Pharmaceuticals之前，亨德森女士曾担任Axerion Therapeutics，Inc.（一家私人持有的生物技术公司）的执行Vice President、首席财务官和业务开发主管，以及Panacos Pharmaceuticals，Inc.（一家公开上市的生物制药公司）的执行Vice President、首席财务官和首席商务官。亨德森女士自2013年10月起担任Eleven Biotherapeutics，Inc.的董事会成员，自2018年1月起担任生物制药公司Ophthotech Corp.的董事会成员。Henderson女士在杜克大学（Duke University）获得心理学学士学位。
Jane Pritchett Henderson has served as our Chief Financial Officer since December 2020. In addition, Ms. Henderson serves as a director and chair of the audit committee of Akero Therapeutics, Inc. since April 2019 of IVERIC bio, Inc. since January 2018 and of Sesen Bio, Inc., formerly Eleven Biotherapeutics, Inc., since October 2013. Prior to joining Adagio, Ms. Henderson served as Chief Financial Officer of Turnstone Biologics from June 2018 to December 2020 Chief Financial Officer and Senior Vice President, Corporate Development of Voyager Therapeutics, Inc. from January 2017 to June 2018 and Senior Vice President and Chief Financial & Business Officer of Kolltan Pharmaceuticals, Inc. from February 2013 to November 2016. Ms. Henderson received a B.S. in Psychology from Duke University.- Jane Pritchett Henderson，亨德森女士自2017年1月起担任我们的首席财务官兼高级副总裁，企业发展。在加入我们之前，亨德森女士曾担任Kolltan制药公司的高级副总裁，首席财务官兼商务官，于2013年2月加入这家私人控股的生物制药公司，并于2016年11月领导将Kolltan出售给Celldex Pharmaceuticals，Inc.。此前，2010年6月至2012年6月，Henderson女士担任ISTAPharmaceuticals，Inc.（一家公开上市的制药公司）的业务发展Vice President，当时ISTA Pharmaceuticals被Bausch+Lomb收购。在加入ista Pharmaceuticals之前，亨德森女士曾担任Axerion Therapeutics，Inc.（一家私人持有的生物技术公司）的执行Vice President、首席财务官和业务开发主管，以及Panacos Pharmaceuticals，Inc.（一家公开上市的生物制药公司）的执行Vice President、首席财务官和首席商务官。亨德森女士自2013年10月起担任Eleven Biotherapeutics，Inc.的董事会成员，自2018年1月起担任生物制药公司Ophthotech Corp.的董事会成员。Henderson女士在杜克大学（Duke University）获得心理学学士学位。
- Jane Pritchett Henderson has served as our Chief Financial Officer since December 2020. In addition, Ms. Henderson serves as a director and chair of the audit committee of Akero Therapeutics, Inc. since April 2019 of IVERIC bio, Inc. since January 2018 and of Sesen Bio, Inc., formerly Eleven Biotherapeutics, Inc., since October 2013. Prior to joining Adagio, Ms. Henderson served as Chief Financial Officer of Turnstone Biologics from June 2018 to December 2020 Chief Financial Officer and Senior Vice President, Corporate Development of Voyager Therapeutics, Inc. from January 2017 to June 2018 and Senior Vice President and Chief Financial & Business Officer of Kolltan Pharmaceuticals, Inc. from February 2013 to November 2016. Ms. Henderson received a B.S. in Psychology from Duke University.
- Rene Russo
Rene Russo自2016年4月起担任我们的董事会成员，并于2016年4月至2018年11月担任Arsanis的总裁兼首席执行官。Russo博士还于2015年7月至2016年4月担任Arsanis的首席发展官。自2019年5月起，Russo博士担任Akrevia Therapeutics，LLC（一家私人控股的生物制药公司，专注于开发免疫肿瘤疗法）的首席执行官。在此之前，Russo博士从2003年到2015年5月被默克收购，在CubistPharmaceuticals，Inc.担任了11年多的各种职务，该公司是一家公共制药开发公司，专注于传染病疗法的开发和商业化，最近被默克收购为其全球医疗事务Vice President。从1999年到2004年，她在百时美施贵宝公司（Bristol-Myers Squibb）担任越来越重要的职务，在那里她开始了她的行业职业生涯，担任工业制药传染病博士后。在加入生物技术行业之前，Russo博士在Robert Wood Johnson University Hospital和Princeton Hospital担任临床职位。Russo医生拿到了她的药以及Rutgers University的B.S.。
Rene Russo has served as our chief executive officer and as a member of our board of directors since May 2019 and as our president since May 2021. She has served as founder and chairman of the board of directors of Adagio Therapeutics, Inc., a biotechnology company, since June 2020. Dr. Russo served as entrepreneur-in-residence at New Enterprise Associates, a venture capital firm, from November 2018 to November 2019. Prior to that, she served as president and chief executive officer of Arsanis, Inc., or Arsanis, a biopharmaceutical company, from April 2016 to November 2018 and as its chief development officer from July 2015 until April 2016. Prior to joining Arsanis, Dr. Russo served in various roles of increasing responsibility over an 11-year period at Cubist Pharmaceuticals, Inc., a pharmaceutical development company, focused on the development and commercialization of infectious disease therapeutics, from 2003 until its acquisition by Merck Research Laboratories, or Merck, a healthcare company, in May 2015 most recently as its vice president, global medical affairs. Dr. Russo served as a member of the board of directors of Arsanis, Inc. since April 2016 and continues to serve as a member of X4 Pharmaceuticals, Inc., a biopharmaceutical company, following its merger with Arsanis in March 2019. Prior to joining the biotechnology industry, Dr. Russo held clinical positions at Robert Wood Johnson University Hospital and Princeton Hospital. Dr. Russo received her Pharm.D. and B.S. from Rutgers University.- Rene Russo自2016年4月起担任我们的董事会成员，并于2016年4月至2018年11月担任Arsanis的总裁兼首席执行官。Russo博士还于2015年7月至2016年4月担任Arsanis的首席发展官。自2019年5月起，Russo博士担任Akrevia Therapeutics，LLC（一家私人控股的生物制药公司，专注于开发免疫肿瘤疗法）的首席执行官。在此之前，Russo博士从2003年到2015年5月被默克收购，在CubistPharmaceuticals，Inc.担任了11年多的各种职务，该公司是一家公共制药开发公司，专注于传染病疗法的开发和商业化，最近被默克收购为其全球医疗事务Vice President。从1999年到2004年，她在百时美施贵宝公司（Bristol-Myers Squibb）担任越来越重要的职务，在那里她开始了她的行业职业生涯，担任工业制药传染病博士后。在加入生物技术行业之前，Russo博士在Robert Wood Johnson University Hospital和Princeton Hospital担任临床职位。Russo医生拿到了她的药以及Rutgers University的B.S.。
- Rene Russo has served as our chief executive officer and as a member of our board of directors since May 2019 and as our president since May 2021. She has served as founder and chairman of the board of directors of Adagio Therapeutics, Inc., a biotechnology company, since June 2020. Dr. Russo served as entrepreneur-in-residence at New Enterprise Associates, a venture capital firm, from November 2018 to November 2019. Prior to that, she served as president and chief executive officer of Arsanis, Inc., or Arsanis, a biopharmaceutical company, from April 2016 to November 2018 and as its chief development officer from July 2015 until April 2016. Prior to joining Arsanis, Dr. Russo served in various roles of increasing responsibility over an 11-year period at Cubist Pharmaceuticals, Inc., a pharmaceutical development company, focused on the development and commercialization of infectious disease therapeutics, from 2003 until its acquisition by Merck Research Laboratories, or Merck, a healthcare company, in May 2015 most recently as its vice president, global medical affairs. Dr. Russo served as a member of the board of directors of Arsanis, Inc. since April 2016 and continues to serve as a member of X4 Pharmaceuticals, Inc., a biopharmaceutical company, following its merger with Arsanis in March 2019. Prior to joining the biotechnology industry, Dr. Russo held clinical positions at Robert Wood Johnson University Hospital and Princeton Hospital. Dr. Russo received her Pharm.D. and B.S. from Rutgers University.
- Tillman U. Gerngross
TillmanU.Gerngross于2010年共同创立了Arsanis，并于2010年8月至2013年8月和2015年12月至2016年4月担任我们的总裁。自2010年8月起担任董事会主席。在加入我们之前，Gerngross博士共同创立了Adimab，LLC，并自2007年以来担任其首席执行官兼董事会主席。Gerngross博士联合创立了多家其他生物技术公司，包括Alector，LLC和Avitide，Inc.，在那里他分别自2014年和2013年以来担任其董事会主席。Gerngross博士目前是SV Health Investors，LLC的风险合伙人，他于2006年加入该公司。Gerngross博士联合创立了Glycofi，Inc.，并从2000年到2006年担任其首席科学官，直到它被Merck收购。Gerngross博士目前任教于生物和化学系，以及达特茅斯学院（Dartmouth College）的工程学院，他自1998年以来一直在那里任教。Gerngross博士就读于奥地利维也纳技术大学（Technical University of Vienna，Austria），在那里他获得化学工程学士学位/硕士学位，后来获得分子生物学博士学位。
Tillman U. Gerngross is our co-founder and has served as a member of our board of directors and as our Chief Executive Officer since June 2020. Dr. Gerngross is a founder, director and executive officer of numerous biotechnology companies. He is a co-founder of Adimab, LLC and has served as its Chief Executive Officer and as a director since 2007. He is also a co-founder and Chairman of Avitide, Inc. since August 2012 a co-founder and Chairman of Alector, Inc. since September 2017 a co-founder, President and Chairman of Amagma, Inc. since August 2019 and a co-founder, President and Chairman of Ankyra Therapeutics, Inc. since November 2019. Dr. Gerngross is currently a Venture Partner at SV Life Sciences Advisors, LLC, which he joined in 2006. Dr. Gerngross co-founded GlycoFi, Inc. and served as its Chief Scientific Officer from 2000 to 2006 until it was acquired by Merck & Company, Inc. Dr. Gerngross currently teaches at the Thayer School of Engineering, at Dartmouth College, where he has taught since 1998. Dr. Gerngross received a B.S. and M.S. in Chemical Engineering and a Ph.D. in Molecular Biology from Technical University of Vienna.- TillmanU.Gerngross于2010年共同创立了Arsanis，并于2010年8月至2013年8月和2015年12月至2016年4月担任我们的总裁。自2010年8月起担任董事会主席。在加入我们之前，Gerngross博士共同创立了Adimab，LLC，并自2007年以来担任其首席执行官兼董事会主席。Gerngross博士联合创立了多家其他生物技术公司，包括Alector，LLC和Avitide，Inc.，在那里他分别自2014年和2013年以来担任其董事会主席。Gerngross博士目前是SV Health Investors，LLC的风险合伙人，他于2006年加入该公司。Gerngross博士联合创立了Glycofi，Inc.，并从2000年到2006年担任其首席科学官，直到它被Merck收购。Gerngross博士目前任教于生物和化学系，以及达特茅斯学院（Dartmouth College）的工程学院，他自1998年以来一直在那里任教。Gerngross博士就读于奥地利维也纳技术大学（Technical University of Vienna，Austria），在那里他获得化学工程学士学位/硕士学位，后来获得分子生物学博士学位。
- Tillman U. Gerngross is our co-founder and has served as a member of our board of directors and as our Chief Executive Officer since June 2020. Dr. Gerngross is a founder, director and executive officer of numerous biotechnology companies. He is a co-founder of Adimab, LLC and has served as its Chief Executive Officer and as a director since 2007. He is also a co-founder and Chairman of Avitide, Inc. since August 2012 a co-founder and Chairman of Alector, Inc. since September 2017 a co-founder, President and Chairman of Amagma, Inc. since August 2019 and a co-founder, President and Chairman of Ankyra Therapeutics, Inc. since November 2019. Dr. Gerngross is currently a Venture Partner at SV Life Sciences Advisors, LLC, which he joined in 2006. Dr. Gerngross co-founded GlycoFi, Inc. and served as its Chief Scientific Officer from 2000 to 2006 until it was acquired by Merck & Company, Inc. Dr. Gerngross currently teaches at the Thayer School of Engineering, at Dartmouth College, where he has taught since 1998. Dr. Gerngross received a B.S. and M.S. in Chemical Engineering and a Ph.D. in Molecular Biology from Technical University of Vienna.
- Lynn Connolly
Lynn Connolly自2020年7月起担任我们的首席医疗官。在加入Adagio之前，Connolly博士于2020年3月至2020年7月担任临床研究高级副总裁，并于2018年3月至2020年2月担任VirBiotechnology，Inc.临床研究副总裁。Connolly博士于2017年1月至2018年3月担任Achaogen，Inc.的副总裁兼后期开发主管，并于2016年1月至2017年1月担任高级医学总监。康诺利博士在加州大学伯克利分校获得分子生物学学士学位，在加州大学旧金山分校获得细胞生物学硕士和博士学位。
Lynn Connolly has served as our Chief Medical Officer since July 2020. Prior to joining Adagio, Dr. Connolly served as Senior Vice President, Clinical Research from March 2020 to July 2020 and Vice President, Clinical Research from March 2018 to February 2020 of Vir Biotechnology, Inc. Dr. Connolly served as Vice President and Head of Late Development from January 2017 to March 2018 and Senior Medical Director from January 2016 to January 2017 of Achaogen, Inc. Dr. Connolly received a B.A. in Molecular Biology from University of California, Berkeley and a M.D. and Ph.D. in Cell Biology from University of California, San Francisco.- Lynn Connolly自2020年7月起担任我们的首席医疗官。在加入Adagio之前，Connolly博士于2020年3月至2020年7月担任临床研究高级副总裁，并于2018年3月至2020年2月担任VirBiotechnology，Inc.临床研究副总裁。Connolly博士于2017年1月至2018年3月担任Achaogen，Inc.的副总裁兼后期开发主管，并于2016年1月至2017年1月担任高级医学总监。康诺利博士在加州大学伯克利分校获得分子生物学学士学位，在加州大学旧金山分校获得细胞生物学硕士和博士学位。
- Lynn Connolly has served as our Chief Medical Officer since July 2020. Prior to joining Adagio, Dr. Connolly served as Senior Vice President, Clinical Research from March 2020 to July 2020 and Vice President, Clinical Research from March 2018 to February 2020 of Vir Biotechnology, Inc. Dr. Connolly served as Vice President and Head of Late Development from January 2017 to March 2018 and Senior Medical Director from January 2016 to January 2017 of Achaogen, Inc. Dr. Connolly received a B.A. in Molecular Biology from University of California, Berkeley and a M.D. and Ph.D. in Cell Biology from University of California, San Francisco.
- Rebecca Dabora
Rebecca Dabora自2020年7月起担任我们的首席技术和制造官。此外，Dabora博士自2005年7月起担任RDBio Consulting LLC的负责人。在加入Adagio之前，Dabora博士于2019年7月至2020年7月担任SwanBio Therapeutics，Inc.的临时首席技术官，并于2016年3月至2017年3月担任Aspyrian Therapeutics，Inc.的首席技术官。达博拉博士获得了鲍多因学院的生物化学学士学位，以及麻省理工学院的应用生物科学和生物化学工程博士学位。
Rebecca Dabora has served as our Chief Technology & Manufacturing Officer since July 2020. In addition, Dr. Dabora is currently serving as Principal for RDBio Consulting LLC since July 2005. Prior to joining Adagio, Dr. Dabora served as Interim Chief Technology Officer of SwanBio Therapeutics, Inc. from July 2019 to July 2020 and Chief Technology Officer of Aspyrian Therapeutics, Inc. from March 2016 to March 2017. Dr. Dabora received a B.A. in Biochemistry from Bowdoin College and a Ph.D. in Applied Biological Sciences and Biochemical Engineering from the Massachusetts Institute of Technology.- Rebecca Dabora自2020年7月起担任我们的首席技术和制造官。此外，Dabora博士自2005年7月起担任RDBio Consulting LLC的负责人。在加入Adagio之前，Dabora博士于2019年7月至2020年7月担任SwanBio Therapeutics，Inc.的临时首席技术官，并于2016年3月至2017年3月担任Aspyrian Therapeutics，Inc.的首席技术官。达博拉博士获得了鲍多因学院的生物化学学士学位，以及麻省理工学院的应用生物科学和生物化学工程博士学位。
- Rebecca Dabora has served as our Chief Technology & Manufacturing Officer since July 2020. In addition, Dr. Dabora is currently serving as Principal for RDBio Consulting LLC since July 2005. Prior to joining Adagio, Dr. Dabora served as Interim Chief Technology Officer of SwanBio Therapeutics, Inc. from July 2019 to July 2020 and Chief Technology Officer of Aspyrian Therapeutics, Inc. from March 2016 to March 2017. Dr. Dabora received a B.A. in Biochemistry from Bowdoin College and a Ph.D. in Applied Biological Sciences and Biochemical Engineering from the Massachusetts Institute of Technology.
- David Hering
David Hering自2021年6月起担任我们的首席运营官。在加入Adagio之前，Hering先生于2021年4月至2021年6月担任Pfizer，Inc.的mRNA全球特许经营业务主管，于2018年12月至2021年4月担任Pfizer，Inc.的北美疫苗总裁，并担任Pfizer的疫苗商务官，Inc.从2015年6月到2018年12月。在2015年加入辉瑞之前，他在诺华疫苗公司（Novartis Vaccines）工作了7年，担任北美地区负责人。Bering先生在哈佛商学院获得工商管理硕士学位，在康奈尔大学获得运营研究和工业工程学士学位。
David Hering has served as our Chief Operating Officer since June 2021. Prior to joining Adagio, Mr. Hering served as the Head of the mRNA Global Franchise Business of Pfizer, Inc. from April 2021 to June 2021 the President of North America Vaccines of Pfizer, Inc. from December 2018 to April 2021 and the Vaccines Commercial Officer of Pfizer, Inc. from June 2015 to December 2018. Before joining Pfizer in 2015 Mr. Hering spent seven years at Novartis Vaccines, where he held the position of Head of the North America Region. Mr. Hering received an M.B.A. from Harvard Business School and a B.S. in Operations Research and Industrial Engineering from Cornell University.- David Hering自2021年6月起担任我们的首席运营官。在加入Adagio之前，Hering先生于2021年4月至2021年6月担任Pfizer，Inc.的mRNA全球特许经营业务主管，于2018年12月至2021年4月担任Pfizer，Inc.的北美疫苗总裁，并担任Pfizer的疫苗商务官，Inc.从2015年6月到2018年12月。在2015年加入辉瑞之前，他在诺华疫苗公司（Novartis Vaccines）工作了7年，担任北美地区负责人。Bering先生在哈佛商学院获得工商管理硕士学位，在康奈尔大学获得运营研究和工业工程学士学位。
- David Hering has served as our Chief Operating Officer since June 2021. Prior to joining Adagio, Mr. Hering served as the Head of the mRNA Global Franchise Business of Pfizer, Inc. from April 2021 to June 2021 the President of North America Vaccines of Pfizer, Inc. from December 2018 to April 2021 and the Vaccines Commercial Officer of Pfizer, Inc. from June 2015 to December 2018. Before joining Pfizer in 2015 Mr. Hering spent seven years at Novartis Vaccines, where he held the position of Head of the North America Region. Mr. Hering received an M.B.A. from Harvard Business School and a B.S. in Operations Research and Industrial Engineering from Cornell University.
- Elham. Hershberger
Elham.Hershberger自2020年6月起担任我们的首席发展官。在加入Adagio之前，Hershberger博士于2017年7月至2020年10月担任EMH Consulting Group，Inc.的总裁，并于2016年1月至2017年7月担任Visterra，Inc.的临床开发主管。赫什伯格博士获得了明尼苏达大学的化学学士学位和药物博士学位。来自费里斯州立大学。
Elham. Hershberger has served as our Chief Development Officer since June 2020. Prior to joining Adagio, Dr. Hershberger served as President of EMH Consulting Group, Inc. from July 2017 to October 2020 and as Head of Clinical Development of Visterra, Inc. from January 2016 to July 2017. Dr. Hershberger received a B.S. in Chemistry from University of Minnesota and a Pharm.D. from Ferris State University.- Elham.Hershberger自2020年6月起担任我们的首席发展官。在加入Adagio之前，Hershberger博士于2017年7月至2020年10月担任EMH Consulting Group，Inc.的总裁，并于2016年1月至2017年7月担任Visterra，Inc.的临床开发主管。赫什伯格博士获得了明尼苏达大学的化学学士学位和药物博士学位。来自费里斯州立大学。
- Elham. Hershberger has served as our Chief Development Officer since June 2020. Prior to joining Adagio, Dr. Hershberger served as President of EMH Consulting Group, Inc. from July 2017 to October 2020 and as Head of Clinical Development of Visterra, Inc. from January 2016 to July 2017. Dr. Hershberger received a B.S. in Chemistry from University of Minnesota and a Pharm.D. from Ferris State University.